La cadena de opciones muestra datos clave de las opciones de acciones de Puig Brands a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Puig Brands..

Puig Brands (OTC:PUGBY) Bolsa, Cadena de Opciones

Puig is a premium beauty product maker that focuses on fragrances (76% of 2024 sales), with more limited exposure to color cosmetics (16%) and skincare (11%). Through a series of acquisitions, Puig has built a premium portfolio, including brands such as Rabanne, Carolina Herrera, Byredo, L'Artisan Parfumeur, Penhaligon's, Dries Van Noten, and Charlotte Tilbury, which contributes 95% of total sales. It also has long-term licensing agreements with Christian Louboutin, Adolfo Dominguez, and Antonio Banderas. Puig generates close to 55% of sales from Europe, 36% from the Americas, and 9% from Asia. The Puig family owns 74% of the economic interests in the company and 93% of the voting rights via a dual-class share structure.

Puig

IDEXY

PUIG BRANDS S.A. U/ADS by PUIG BRANDS S A

PUGBY

Las acciones de Puig enfrentan mínimos históricos mientras la compañía reporta sólido crecimiento y perspectivas positivas para 2025.

Acciones de Puig muestran potencial oculto pese a desplome bursátil y presión de aranceles

BBVA

Las acciones de Puig combinan alto potencial de revalorización con desafíos operativos que podrían limitar ganancias inmediatas.

Acciones de Puig atraen inversores tras recomendaciones mixtas de Berenberg y GVC Gaesco

Las acciones de Puig suben tras superar expectativas de ventas. ¿Qué opinan los analistas y qué impacto tiene en el mercado?

Acciones de Puig se disparan en el Ibex 35 tras superar expectativas: ¿Qué dicen los analistas?

Puig Brands SA

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 115.15 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $2.74 million which beat the analyst consensus estimate of $2.00 million by 36.95 percent. This is a 95.10 percent decrease over sales of $55.90 million the same period last year.

Earnings

Earnings Beats

News

FGEN

FibroGen Q1 EPS $0.05 Beats $0.02 Estimate, Sales $2.74M Beat $2.00M Estimate

<ul>
<li>A pre-tax present value commitment of approximately $210 million to resolve the legacy Chambers Works litigation and other elements of the settlement.
<ul>
<li>A pre-tax present value commitment of approximately $75 million to resolve current and future statewide claims starting in 2030 and running through 2050.</li>
</ul>
</li>
</ul>

Legal

3M Resolves PFAS-Related Claims With State Of New Jersey; Expects To Record Pre-Tax Charge Of ~$285M In Q2

ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 18.75 percent increase over losses of $(0.16) per share from the same period last year. The company reported $230.00 thousand in sales this quarter.

PROK

ProKidney Q1 EPS $(0.13) Beats $(0.16) Estimate, Sales $230.00K

Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $23.84 million which missed the analyst consensus estimate of $24.18 million by 1.39 percent. This is a 11.85 percent increase over sales of $21.31 million the same period last year.

Earnings Misses

GAIA

Gaia Q1 EPS $(0.04), Inline, Sales $23.84M Miss $24.18M Estimate

Amplify Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.16 by 43.75 percent. This is a 137.5 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $72.05 million which missed the analyst consensus estimate of $73.87 million by 2.46 percent. This is a 5.57 percent decrease over sales of $76.30 million the same period last year.

AMPY

Amplify Energy Q1 Adj. EPS $0.09 Misses $0.16 Estimate, Sales $72.05M Miss $73.87M Estimate

GPRO

GoPro Q1 Adj. EPS $(0.12), Inline, Sales $134.00M Beat $124.65M Estimate

Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.05) by 180 percent. This is a 275 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $68.43 million which missed the analyst consensus estimate of $72.04 million by 5.01 percent. This is a 5.81 percent decrease over sales of $72.65 million the same period last year.

QRHC

Quest Resource Holding Q1 Adj. EPS $(0.14) Misses $(0.05) Estimate, Sales $68.43M Miss $72.04M Estimate

Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) lowers FY2025 sales outlook from $47.00 million-$56.00 million to $44.00 million-$50.00 million vs $49.60 million estimate.

Guidance

AQST

Aquestive Therapeutics Lowers FY2025 Sales Guidance from $47.00M-$56.00M to $44.00M-$50.00M vs $49.60M Est

Shares of regional banks such as Associated Banc-Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) and BankUnited Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) are trading higher Monday afternoon following news of a major tariff rollback agreement <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">between the U.S. and China.</a>
What To Know: The gains come as the 90-day trade truce between the two countries is expected to reduce macroeconomic uncertainty, particularly in lending and capital markets.
The tariff rollback deal, reached after talks in Geneva, cuts U.S. tariffs on Chinese goods from 145% to 30% and reduces Chinese tariffs on U.S. goods from 125% to 10%, effective May 14. Both countries signaled that the pause is aimed at stabilizing global trade and preventing further economic disruption caused by the sharp tariff hikes imposed in April. For banks, this clarity is key to improving the outlook for credit markets, deal-making and borrower confidence.
With tariffs no longer clouding the near-term economic picture, recession odds have fallen significantly. According to market data from Kalshi, the probability of a U.S. recession this year has dropped to 46%, down from 60% just two weeks ago. Banking stocks, often seen as barometers of economic health, have responded positively as investors bet on improving loan demand and reduced risk exposure.
The broader market rally also added momentum, with the S&amp;P 500 futures gaining over 3%, Nasdaq futures rising more than 4%, and Dow futures climbing above 2.6%. Treasury yields rose and the dollar strengthened, indicating that investors are shifting back into risk assets and pulling away from recession hedges like gold.
For mid-sized banks like Associated Banc-Corp and BankUnited, which are heavily tied to regional lending and business investment activity, a more stable trade environment means stronger deal flow, reduced credit risk and better earnings visibility heading into the second half of the year.
ASB, BKU Price Action: Associated Banc-corp shares closed up 5.19% to $24.41 and BankUnited shares closed up 5.20% to $35.61, on Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45357613/china-tariff-de-escalation-biggest-winners-include-tesla-apple-new-tech-highs-back-on-the-table-now-for-2025">China Tariff De-Escalation Biggest Winners Include Tesla, Apple: &#8216;New Tech Highs Back On The Table Now For 2025&#8217;</a> Photo: Shutterstock<a href="https://www.benzinga.com/tech/25/05/45357613/china-tariff-de-escalation-biggest-winners-include-tesla-apple-new-tech-highs-back-on-the-table-now-for-2025"> </a></li>
</ul>

Movers

Bank Stocks Rise As US–China Tariff Truce Lifts Market Confidence: What's Going On?

Radiant Logistics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RLGT#AMEX">RLGT</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.07 by 100 percent. This is a 75 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $214.01 million which beat the analyst consensus estimate of $194.03 million by 10.30 percent. This is a 15.96 percent increase over sales of $184.56 million the same period last year.

RLGT

Radiant Logistics Q3 Adj. EPS $0.14 Beats $0.07 Estimate, Sales $214.01M Beat $194.03M Estimate

MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) affirms FY2025 sales outlook from $326.00 million-$334.00 million to $326.00 million-$334.00 million vs $328.93 million estimate.

MLNK

MeridianLink Affirms FY2025 Sales Guidance of $326.00M-$334.00M vs $328.93M Est

Management

MeridianLink Plans To Appoint Larry Katz To CEO In Oct. 2025

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.37 per share which missed the analyst consensus estimate of $0.38 by 2.63 percent. This is a 15.91 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $24.95 million which missed the analyst consensus estimate of $26.62 million by 6.28 percent. This is a 4.02 percent decrease over sales of $26.00 million the same period last year.

Stellus Cap Investment Q1 Adj. EPS $0.37 Misses $0.38 Estimate, Sales $24.95M Miss $26.62M Estimate

MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.12 by 25 percent. This is a 50 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $81.49 million which beat the analyst consensus estimate of $80.76 million by 0.90 percent. This is a 4.72 percent increase over sales of $77.82 million the same period last year.

MeridianLink Q1 Adj. EPS $0.09 Misses $0.12 Estimate, Sales $81.49M Beat $80.76M Estimate

Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 41.18 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $8.72 million which missed the analyst consensus estimate of $12.23 million by 28.70 percent. This is a 27.65 percent decrease over sales of $12.05 million the same period last year.

Aquestive Therapeutics Q1 EPS $(0.24) Misses $(0.17) Estimate, Sales $8.72M Miss $12.23M Estimate

Atea Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVIR#NASDAQ">AVIR</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 46.67 percent increase over losses of $(0.75) per share from the same period last year.

AVIR

Atea Pharmaceuticals Q1 EPS $(0.40) Beats $(0.41) Estimate

Brink's Sees Q2 Adj EPS $1.25-$1.65 vs $1.17 Est; Sees Sales $1.250B-$1.300B vs $1.21B Est

Equitable Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>) has outperformed the market over the past 5 years by 11.45% on an annualized basis producing an average annual return of 26.73%. Currently, Equitable Holdings has a market capitalization of $16.52 billion. 
Buying $1000 In EQH: If an investor had bought $1000 of EQH stock 5 years ago, it would be worth $3,299.08 today based on a price of $53.94 for EQH at the time of writing.
<h3>Equitable Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747080915_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Equitable Holdings Stock In The Last 5 Years

FutureFuel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FF#NYSE">FF</a>) reported quarterly losses of $(0.40) per share. This is a 500 percent decrease over earnings of $0.10 per share from the same period last year. The company reported $17.54 million in sales this quarter. This is a 69.91 percent decrease over sales of $58.28 million the same period last year.

Comments

Puig Brands

Puig Brands (PUGBY) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL